Vice President, NovaQuest

Ben Cons, PhD, Vice President of NovaQuest, structures and delivers managed partnerships with pharmaceutical and biotechnology industries in Europe and the U.S. He has participated in over $1 billion of tailored financial solutions by leveraging the intellectual capital, management and financial resources of NovaQuest and Quintiles. In addition to his role as deal architect, Dr. Cons is responsible for delivering the strategic plan for NovaQuest, including relationships with venture capital groups, private equity groups and investment banks. An innovative team leader, he is adept in developing partnership solutions between companies that realize value for all parties.

Dr. Cons joined Quintiles in 1996, bringing his expertise in pharmaceutical drug development and commercialization to drive corporate development goals. He became a part of the PharmaBio Development Group (NovaQuest predecessor) in 2003. Early on in his career, Dr. Cons expanded his research experience in molecular pharmacology through a position in drug development for Schering AG. Later, at Glaxo Wellcome, he developed an expertise in marketing and business development, particularly through a joint venture with Reuters.

Educated in the U.K., Dr. Cons acquired a bachelor’s degree in biological sciences with honors from Portsmouth Polytechnic, and then continued his studies to earn a doctorate in molecular pharmacology within the physiology and pharmacology department of Southampton University.